Edward Painter's Email & Phone Number

💼 Past Experience

Chairman and Chief Investment Officer at A2A Pharmaceuticals Inc. Edward Painter is currently a Analyst at Salomon Brothers from 1984 to 1987 (3 years). Corporate bond research. Business Development Executive at Startup Pharmaceutical Company from June 2015 to February 2016 (9 months). Evaluation of business and financing opportunities. Investor and investment bank and relationship management. Managing Member at SHomer Capital LLC in New York NY. Financial Advisory Services focused on the Biotechnology Industry, Leveraging breakthrough computational chemistry to develop new drug candidates for Oncology and Infectious Diseases. Senior Vice President at Oppenheimer & Co. from 1995 to 1998 (3 years) in New York NY. Institutional Equity Sales. Vice President at Credit Suisse from July 1992 to July 1995 (3 years 1 month) in New York. Institutional Fixed Income Sales. Vice President at Kidder Peabody from July 1990 to July 1992 (2 years 1 month) in Greater New York City Area. Institutional Fixed Income Sales. Analyst at Goldman Sachs from 1987 to 1990 (3 years). Corporate and mortgage bond research. Founder, Chairman and Chief Investment Officer at A2A Pharmaceuticals Inc in New York, New York. A2A Pharmaceutical's pipeline consists of new drug candidates focused on mixed-lineage leukemia (MLL), Kras degradation and YAP/TEAD solid tumor mechanisms of action. Founder and Chief Executive Officer at A2A Pharmaceuticals from March 2016 to July 2019 (3 years 5 months) in Greater New York City Area. A2A Pharmaceutical's pipeline consists of new drug candidates focused on mixed-lineage leukemia (MLL) and YAP/TEAD solid tumor mechanisms of action. The ADMET properties and potency statistics in the AO-001 and AO-002 programs are dramatically better than alternatives. The infectious disease research at A2A is focused on the LpxC and AroK targets for gram-negative bacteria infections. Senior Vice President at UBS Investment Bank from 1998 to May 2015 (17 years) in New York NY. Institutional & UHNW Sales.

🎓 Education

Edward Painter's education has been focused in finance and business. He earned his MBA from the University of Illinois at Urbana-Champaign in 1984, and then went on to obtain his B.A. from Illinois Wesleyan University in 1980. Painter has had previous experience in management and marketing, and is currently a practicing business accountant.In his professional career, Painter has worked with various companies. He has most recently been with PricewaterhouseCoopers LLP as a business accountant. Painter is currently also a visiting professor at the University of Illinois at Urbana-Champaign's College of Business.

💡 Technical & Interpersonal Skills

Edward Painter has extensive experience in Hedge Funds, Corporate and Mortgage Bonds, Investment Banking, Corporate Finance, Investor/Investment Bank, Investment Accounting, Financial Advisory Services, and Infectious Disease Research. He has also been active in the chemical business and has experience in the development of drugs for oncology and infectious diseases. A Chairman and Chief Investment Officer at A2A Pharmaceuticals, he is currently responsible for developing new drug candidates for MLL, Kras degradation and YAP/TEAD solid tumors. As a Senior Vice President at Oppenheimer & Co. from 1995 to 1998, he was responsible for managing institutional equity sales and Fixed Income Sales. He also had an involvement in institutional fixed income sales at Kidder Peabody from 1990 to 1992 and at Goldman Sachs from 1987 to 1990. Mr. Painter is also a Founding Chairman and Chief Investment Officer at A2A Pharmaceuticals. This company provides a pipeline of new drug candidates specific to the treatment of mixed-lineage leukemia and solid tumor mechanisms of action.